AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00139399 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery bypass graft (CABG) surgery
Description: Patients were randomized to receive either a radial artery or a long saphenous vein graft to the left circumflex coronary artery territory during CABG surgery
Study NCT04044612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medial Unloader Brace
Description: medial knee unloader braces use a three point bending system to increase space in the medial tibiofemoral compartment during weight bearing
Study NCT02961751 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ciprofloxacin
Description: Directly observed treatment with a single dose of ciprofloxacin 500 mg orally with or without food.
Study NCT02359357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03604588 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HPV OncoTect™
Description: Salivary specimens will be collected from 40 patients with oropharyngeal cancer The saliva samples will be sent to incell dx, which will analyze them blindly (without knowledge of the clinicopathological information) with the HPV OncoTect ™ test.~Clinical and pathological information will be collected and maintained by the principal investigator At the end of the study, the results obtained with the HPV OncoTect ™ test will be confronted with the clinical and pathological results.
Study NCT01838330 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: psyllium
Description: 15 grams/day for 1 week, followed by 30 grams/day for 4 months
Study NCT02320812 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human retinal progenitor cells
Description: single intravitreal injection of 0.5 - 3.0 million human retinal progenitor cells (hRPC)
Study NCT04502420 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lung function before and after surgery
Description: A diagnostic test
Study NCT02298803 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Holter and Glucose monitoring
Description: (i) Continuous Glucose Monitoring A sterile disposable glucose-sensing sensor will be inserted into the subcutaneous tissues in either the abdomen or the upper outer quadrant of the patient's buttock. This sensor automatically measures the change in glucose in interstitial fluid every 5 minutes. The monitor will be worn for two days.~(ii)Holter Monitoring The Holter monitor to capture cardiac conduction, specifically QT interval, will be worn for the same period as the continuous glucoe monitor with study participants encouraged to perform regular daily activities.
Study NCT00893555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: voriconazole (dosing according to the SPC)
Description: No serum concentrations are determined
Study NCT02383043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine
Study NCT02383043 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocaine
Study NCT02383043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sustained Release d-Amphetamine
Study NCT02383043 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sustained Release d-Amphetamine
Study NCT01571050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Purified water
Description: Ingestion of 30 mL of purified water
Study NCT06100159 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tympanostomy tube insertion
Description: Ventilation tube insertion in the tympanic membrane
Study NCT01571050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fresh MFP/CaCO3 toothpaste
Description: Ingestion of 31.9 mg of a fresh toothpaste containing 1450 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight.
Study NCT01571050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fresh NaF/SiO2 toothpaste
Description: Ingestion of 49.5 mg of a fresh toothpaste containing 1100 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight.
Study NCT01571050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aged NaF/SiO2 toothpaste
Description: Ingestion of 49.5 mg of a toothpaste containing 1100 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight. The toothpaste had been previously aged to simulate one year storage at room temperature.
Study NCT01571050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aged MFP/CaCO3 toothpaste
Description: Ingestion of 31.9 mg of a toothpaste containing 1450 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight. The toothpaste had been previously aged to simulate one year storage at room temperature.
Study NCT03003221 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AIR-P Dental Toolkit
Description: The AIR-P Dental Toolkit is designed to provide caregivers with guidance and information related to dental care and support strategies for children with autism spectrum disorder.
Study NCT03003221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AIR-P Dental Toolkit
Description: The AIR-P Dental Toolkit is designed to provide caregivers with guidance and information related to dental care and support strategies for children with autism spectrum disorder.
Study NCT03003221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Training
Description: The parent-training intervention integrates strategies shown to be efficacious for: 1) improving adherence to dental care, 2) enhancing dental experiences for children with neurotypical development and high levels of dental fear, and 3) evidence-based behavioral techniques established for children with autism spectrum disorder.
Study NCT02227953 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yband (YDT-201N)
Description: transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 20 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
Study NCT02227953 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-Yband (YDT-201N)
Description: transcranial Direct Current Stimulation (tDCS) 2mA for 20 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
Study NCT00769925 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy-Primary Care
Description: Children will receive cognitive behavioral therapy from a child anxiety specialist at their doctor's office (the primary care clinic). The children will learn skills to cope with fear and anxiety, and parents will learn how to support their children in using these new skills.
Study NCT00769925 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist-Assisted Bibliotherapy-Primary Care
Description: Parents will receive educational workbooks and ongoing support over the phone from a child anxiety specialist to learn how to use cognitive behavioral therapy skills to manage their children's fears and worries.
Study NCT03392389 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1653
Description: Escalating dose levels
Study NCT03392389 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT01261442 — intervention group
Intervention type: PROCEDURE
Intervention: Nerve Conduction Study (NCS)
Description: An NCS will be performed on each patient to confirm or exclude DSPN. Following this, a systematic ultrasound examination of the posterior tibial nerve will be performed for all the patients.
Study NCT03316664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Neurocognitive Therapy (INT)
Description: Information already included in arm/group description.
Study NCT03316664 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Psychological Therapy (IPT)
Description: Information already included in arm/group description.
Study NCT03316664 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: COGPACK
Description: Information already included in arm/group description.
Study NCT02927080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-083
Description: Recombinant fusion protein.
Study NCT01131468 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: N-acetylcysteine
Description: N-acetylcysteine 600 mg twice daily or vancomycine+amikacin alone
Study NCT01131468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: N-acetylcysteine 600 mg twice daily or vancomycine+amikacin alone
Study NCT05002439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent physical exercise program and a nutritional intervention
Description: The exercise program will be delivered by trained experts in groups of 6 participants, and will be based on the recommendations presented in the Spanish Healthcare Ministry document. This program includes balance, flexibility, and strength and power exercises. The program will be realized twice a week, during 45 minutes time, for 16 weeks, twice a year. Nutritional intervention will be based on the results of MNA-SF. If the results of this instrument show normal nutrition status, general nutritional recommendations will de presented by a nutritionist twice a year before the physical exercise program. If MNA-SF shows nutritional risk or malnutrition, oral nutritional supplementation will be offered. Primary Care Physicians will have the opportunity of referring high risk participants to their Geriatrics Department Participants when appropriate, following Healthcare Ministry algorithm
Study NCT04171141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07062119
Description: PF-07062119
Study NCT04171141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD1
Description: Anti-PD1 PF-06801591
Study NCT04171141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-VEGF
Description: Anti-VEGF IV (bevacizumab)
Study NCT03909282 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumpectomy
Description: Standard of Care surgery for DCIS (either lumpectomy or mastectomy)
Study NCT01868620 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iontophoretic CXL
Study NCT01868620 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard CXL
Study NCT03876015 — intervention group
Intervention type: DRUG
Intervention: Semaglutide
Description: Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
Study NCT01375868 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Silgard
Description: vaccination with tetravalent antiviral vaccine
Study NCT02023801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aurora Endometrial Ablation System
Description: Ablation of the endometrial lining of the uterus using the Aurora System
Study NCT02489708 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cessation Counseling
Description: Nurses will be trained to use Electronic Medical Record system to counsel families about second hand smoke exposure. Saliva samples will be obtained from 15 children at baseline and at follow-up to explore the effects of the nurse intervention.
Study NCT02241811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% Sodium Pentaborate Pentahydrate
Description: For the interventional group after wound dressing we applied hydrogel with 3% Sodium pentaborate pentahydrate everyday for two months. The same doctor observed and took photo of the wounds every week in the outpatients clinic.
Study NCT02241811 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Hydrogel without 3% Sodium Pentaborate Pentahydrate
Study NCT02125916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oxygen therapy
Study NCT05062304 — intervention group
Intervention type: DRUG
Intervention: Fluticasone Furoate-Vilanterol Trifenatate
Description: Fluticasone Furoate-Vilanterol Trifenatate dispensing claim is used as the reference group.
Study NCT05062304 — intervention group
Intervention type: DRUG
Intervention: Furoate-umeclidinium-vilanterol
Description: Furoate-umeclidinium-vilanterol dispensing claim is used as the exposure group.
Study NCT02727387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEMIRI
Description: Window therapy frontline for VHR patients
Study NCT02727387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADM
Description: Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Etoposide
Study NCT02727387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFO
Description: Drug used in the Induction phase in association with Vincristine, Adriamycin, cyclophosphamide and Etoposide
Study NCT02727387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYC
Description: Drug used in the Induction phase in association with Vincristine, Ifosfamide, Adriamycin and Etoposide
Study NCT02727387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETO
Description: Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Adriamycin
Study NCT02727387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BUMEL
Description: Consolidation phase
Study NCT02727387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIN
Description: Drug used in the Induction phase in association with cyclophosphamide , Ifosfamide, Adriamycin and Etoposide
Study NCT01771848 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: Aseptic, purified, vialed, cryopreserved fully infectious NF54 P. falciparum sporozoites
Study NCT01648296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FluorbetaOx
Description: Fluorine 18-labeled FluorbetaOx
Study NCT04027049 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supine cycle ergometry of the lower extremities
Description: The cycle ergometer allows for movement of the lower extremities by a motor if a patient is experiencing a disorder of consciousness or is otherwise unable to move one or both legs. If a patient is able to cycle actively the device allows the patient to move patient's legs without support of the motor.
Study NCT02538419 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CPAP + Peer Support
Study NCT02538419 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CPAP + Individual Education
Study NCT03256903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxyflurane
Description: Up to two inhalers containing 3 mL methoxyflurane. Treatment duration: 1 administration in 1 day.
Study NCT03256903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Any kind of analgesia, administered by any route for emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain
Study NCT04189653 — intervention group
Intervention type: OTHER
Intervention: Continuous Monitoring
Description: Wireless continuous vital sign monitoring (HR, RR, SBP/DBP, SAT)
Study NCT03204799 — intervention group
Intervention type: OTHER
Intervention: Metformin
Description: newly diagnosed type 2 diabetes patients who start to metformin monotherapy
Study NCT03204799 — intervention group
Intervention type: DRUG
Intervention: SGLT2 inhibitor
Description: newly diagnosed type 2 diabetes patients who start to SGLT2 inhibitor monotherapy
Study NCT03204799 — intervention group
Intervention type: DRUG
Intervention: ezetimibe
Description: newly diagnosed dyslipidemia patients who start to ezetimibe therapy
Study NCT01725230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: 100-mg tablet
Study NCT01725230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 20-mg tablet
Study NCT01725230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 40-mg tablet
Study NCT02752958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: stannous fluoride
Description: 0.454% w/w (weight per weight) stannous fluoride
Study NCT00883870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: Intramuscular injection
Study NCT00883870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasmalyte A
Description: Intramuscular injection
Study NCT02927080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ACE-083 or placebo
Description: Recombinant fusion protein or normal saline.
Study NCT04040478 — intervention group
Intervention type: DEVICE
Intervention: Transcutaneous monitoring
Description: Transcutaneous monitoring of oxygen and carbon dioxide by using Radiometer TCM5 flex monitor with 3 electrodes on the patient.~Abdominal patients are monitored for 4 hours during surgery and for 2 hours in the Post-Anesthesia Care Unit. Arterial blood gasses are drawn from the arterial line 4 times during surgery and 4 times after surgery.~Patients undergoing vascular surgery are monitored for up to 4 hours during surgery.
Study NCT01382056 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control foods
Description: pulse-free control foods consumed daily, 5 days per week for 8 weeks
Study NCT01382056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed bean (higher amount)
Description: 0.6 cup of mixed beans consumed 5 days per week for 8 weeks
Study NCT01382056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed beans (lower amount)
Description: 0.3 cup of mixed beans consumed daily, 5 days per week for 5 weeks
Study NCT01448785 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: abiliti system implant
Description: Subjects will receive implanted abiliti System.
Study NCT02837094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C19-A3 GNP
Description: C19A3 GNP intradermal microinjectable solution of human C19A3 proinsulin peptide coupled to gold.
Study NCT02300584 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-Savvy
Description: as a program delivered on an iPad with daily instructional video segments (8-12 minutes each)
Study NCT02300584 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-Savvy
Description: as a program delivered on an iPad with daily instructional video segments (8-12 minutes each). Videos may be modified after feedback from Prototype arm.
Study NCT02300584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iPad
Description: a tablet computer with an internet connection
Study NCT01448785 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic adjustable gastric band (Allergan Lap Band)
Description: Subjects will receive an implanted laparoscopic adjustable gastric band. Specific brand is at the investigator's discretion.
Study NCT02030080 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives
Study NCT02030080 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Teams
Study NCT02030080 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teams
Study NCT04076319 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CAPABLE: Community Aging in Place-Advancing Better Living for Elders
Description: CAPABLE is a client-directed home-based intervention that consists of time-limited services from an occupational therapist, a nurse, and a handyman working collaboratively with the older adult client. In most cases, the OT makes 6 visits, the RN makes 4 visits, and a handyman makes 1 to 2 visits to make any modifications to a person's home during a 6-month period. The first visits for the OT and RN are usually 90 minutes each and the later ones are usually an hour each. Visits are spaced to enable older adults to practice new strategies learned in the previous visit. There should be a clear conclusion/graduation, with the older adult understanding how to use their new skills and apply them to future situations.
Study NCT01821521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGSPT_L20
Study NCT01821521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoloc 40mg
Study NCT03205033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 20 MG Oral Capsule
Description: 1 capsule/day 1 hour before go to bed
Study NCT03205033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: 1 capsule/day 1 hour before go to bed
Study NCT01497691 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIPPV (PALMtop PTV)
Description: PALMtop PTV Models 8/10 aka CareFusion EnVe The primary study device is the PALMtop PTV. It is the NIPPV/BiPAP device used in this study. It is FDA approved for use in children who weigh 5 kilograms or greater (#K070594).
Study NCT01497691 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NIPPV (PALMtop PTV)
Description: PALMtop PTV Models 8/10 aka CareFusion EnVe The primary study device is the PALMtop PTV. It is the NIPPV/BiPAP device used in this study. It is FDA approved for use in children who weigh 5 kilograms or greater (#K070594).
Study NCT01497691 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Volumetric CO2 (NM3)
Description: The NM3 is FDA approved (#K091459) for spirometric and carbon dioxide monitoring as well as continuous, non-invasive monitoring of arterial oxygen saturations and pulse rates in neonatal and pediatric patients in the emergency department.